Terumo BCT Awarded Cost-Share Contract Worth Up to $29.9M for Research and Development Effort with the U.S. Department of Defense

Terumo BCT Awarded Cost-Share Contract Worth Up to $29.9M for Research and Development Effort with the U.S. Department of Defense

<0> Terumo BCTLaura Fusco, +1-303-205-2546Global Corporate Communications </0>

Terumo BCT has been awarded a U.S. Department of Defense (DoD) cost-share contract worth up to $29.9M to advance the for the treatment of donated whole blood used in emergency transfusions in deployed military forces.

“We are pleased to partner with the U.S. Army in advancing the development of the Mirasol system for whole blood, a critical resource developed to help improve the medical support capabilities for our soldiers in the field. With this collaboration, we aim to provide the best possible transfusion medicine option for war fighters and further Terumo BCT's mission to improve lives through innovation, quality and service.”

“The Mirasol system for whole blood provides the potential for safe blood products in environments where this is not possible or practical today. Its use could change the way in which blood is made available to people on a global basis.”

“Enhancing the safety of military blood products while retaining therapeutic efficacy is critical to the treatment of wounded service members on the battlefield, and is among the highest priorities of the Defense Medical Research and Development Program. Under this contract, Terumo BCT will perform critical studies toward FDA clearance of the Mirasol system for whole blood, a pathogen reduction device intended to decrease the risk of blood transfusion associated with bacteria, viruses, parasites and white blood cells.”

The Mirasol system is not FDA-approved for sale in the United States.

USAMMDA develops new drugs, vaccines and medical support equipment that enhance readiness, ensure the provision of the highest quality medical care to the DoD, and maximize survival of medical casualties on the battlefield.

, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.